CD226 Immune Receptor Explored as Predictor of Immunotherapy Response in Advanced Liver Cancer
A French trial investigated whether circulating immune cell profiles, specifically CD226 expression, could predict who responds to Atezolizumab/Bevacizumab in advanced HCC.
Summary
Advanced hepatocellular carcinoma (liver cancer) carries a grim prognosis, and while the Atezolizumab plus Bevacizumab combination has improved outcomes, only about one-third of patients respond. This French trial aimed to determine whether measuring the frequency and phenotype of circulating immune cells — particularly expression of the CD226 receptor on T cells and NK cells — before and after treatment could predict who would benefit. Blood samples were planned at baseline and three weeks into therapy. Unfortunately, the trial was terminated early after enrolling only 4 of its intended participants, meaning no meaningful efficacy data were generated. The concept remains scientifically compelling: CD226 promotes immune cell cytotoxicity and has emerged as a novel immunotherapeutic target across multiple cancer types, making it a plausible biomarker candidate.
Detailed Summary
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death globally, and advanced-stage disease has historically been treated with multikinase inhibitors like sorafenib — agents associated with limited survival benefit and significant toxicity. The landscape shifted meaningfully with the IMbrave150 trial, which demonstrated superior outcomes for the combination of Atezolizumab (anti-PD-L1) and Bevacizumab (anti-VEGF) compared to sorafenib, establishing this doublet as the new first-line standard of care for advanced HCC.
Despite this progress, a critical challenge remains: only approximately one-third of patients respond to Atezolizumab/Bevacizumab. Identifying reliable predictive biomarkers could allow clinicians to stratify patients before treatment, sparing non-responders from unnecessary toxicity and cost while accelerating access to alternative strategies.
This prospective French trial, sponsored by Assistance Publique – Hôpitaux de Paris, set out to evaluate circulating immune cell profiles as a candidate biomarker. Specifically, investigators focused on CD226 (also known as DNAM-1), a transmembrane activating receptor expressed on CD8+ T cells, CD4+ T cells, and natural killer (NK) cells. CD226 enhances cytotoxic immune activity and has been identified as a novel immunotherapeutic target in both solid and hematologic cancers. The trial planned serial blood draws at baseline and three weeks after the first Atezolizumab/Bevacizumab infusion to track CD226 expression changes and correlate them with treatment response.
Unfortunately, the trial was terminated before generating meaningful data, with only 4 patients enrolled out of the intended sample. No results are available.
Despite early termination, the scientific rationale remains highly relevant. CD226 pathway modulation is an active area of oncology research, and non-invasive blood-based immune profiling represents an attractive, practical approach to treatment personalization in HCC. Future, adequately powered studies are needed to test this hypothesis.
Key Findings
- Only ~1 in 3 advanced HCC patients respond to Atezolizumab/Bevacizumab, highlighting urgent need for predictive biomarkers.
- CD226 (DNAM-1) receptor on T cells and NK cells was the primary biomarker candidate under investigation.
- The trial was terminated prematurely with only 4 enrollees, producing no efficacy or biomarker outcome data.
- CD226 is an emerging immunotherapeutic target active in both solid tumors and blood cancers.
- Serial blood-based immune phenotyping was proposed as a minimally invasive response prediction strategy.
Methodology
This was a prospective, single-arm observational trial enrolling patients with advanced HCC initiating first-line Atezolizumab/Bevacizumab. Circulating immune cell frequency and CD226 phenotyping were planned at baseline and at three weeks post-first infusion. The trial was terminated early after enrolling only 4 participants, precluding any statistical analysis.
Study Limitations
The trial was terminated early with only 4 enrollees, rendering it statistically underpowered and unable to draw any conclusions about CD226 as a predictive biomarker. No results data are publicly available. This summary is based on the abstract and trial registry record only, not full-text data.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.